Zubsolv is a prescription sublingual tablet used to treat opioid dependence. It combines two active ingredients, buprenorphine and naloxone, and is FDA-approved as part of a complete treatment plan that includes counseling and psychosocial support. If you or someone you know has been prescribed Zubsolv or is exploring treatment options for opioid use disorder, here’s what you need to know about how it works, what to expect, and how it compares to similar medications.
How Zubsolv Works
Buprenorphine, the primary ingredient, is a partial opioid agonist. That means it activates the same receptors in your brain that opioids like heroin or prescription painkillers target, but it does so much more weakly. This partial activation is enough to reduce withdrawal symptoms and cravings without producing the intense high of a full opioid. It also has a ceiling effect: after a certain dose, taking more doesn’t increase the opioid effects, which lowers the risk of overdose.
Naloxone, the second ingredient, serves as a safeguard against misuse. If someone were to crush and inject the tablet instead of taking it as prescribed, the naloxone would block opioid receptors and trigger withdrawal symptoms. When taken correctly under the tongue, naloxone is poorly absorbed and has minimal effect. Its presence in the formulation is primarily a deterrent.
How Zubsolv Differs From Suboxone
Zubsolv and Suboxone contain the same two active ingredients, but their doses aren’t interchangeable milligram for milligram. Zubsolv is formulated with higher bioavailability, meaning your body absorbs more of the medication from a smaller tablet. A 5.7 mg Zubsolv tablet delivers the same buprenorphine exposure as an 8 mg Suboxone tablet, with about 12% less naloxone exposure. So if you’re switching between products, the numbers on the label will look different even though the therapeutic effect is equivalent.
Beyond the dosing math, there are practical differences. In a study comparing the formulations, Zubsolv dissolved under the tongue in about 5 minutes compared to 12.5 minutes for Suboxone tablets. Zubsolv uses menthol flavoring and a sweetener to mask the bitter taste of buprenorphine, and 96% of study participants preferred Zubsolv’s taste over Suboxone film. Nearly 78% preferred it over the Suboxone tablet as well. These details matter because opioid dependence treatment is long-term, and a medication that’s more tolerable day after day can make a real difference in whether people stick with it.
Available Strengths
Zubsolv comes in four dosage strengths, each with a distinct tablet shape for easy identification:
- 1.4 mg/0.36 mg (triangular)
- 5.7 mg/1.4 mg (round)
- 8.6 mg/2.1 mg (diamond)
- 11.4 mg/2.9 mg (capsule-shaped)
The first number is buprenorphine, the second is naloxone. Your prescriber will determine the right strength based on your level of opioid dependence and how you respond during the early phase of treatment.
How to Take It
Zubsolv is placed under the tongue and left to dissolve completely. You should not chew, crush, or swallow the tablet, since swallowing it significantly reduces absorption and effectiveness. Most people find it dissolves in about 5 minutes. Avoid eating or drinking anything until the tablet is fully dissolved. If your prescribed dose requires more than one tablet, they can be placed under the tongue at the same time or one after the other.
Common Side Effects
Side effects are most noticeable during the first weeks of treatment and tend to improve over time. In clinical trials of patients taking the medication for 16 weeks, the most frequently reported issues were headache (30%), insomnia (25%), pain (24%), and withdrawal-like symptoms (22%). These withdrawal symptoms don’t mean the medication isn’t working. They reflect the body adjusting from full opioid use to a partial agonist.
Other commonly reported effects include sweating (12%), constipation (11%), anxiety (12%), depression (11%), and nausea (10%). During the initial induction phase, when the medication is first started, about 26% of patients in trials reported some type of adverse reaction, with headache, nausea, and vomiting each occurring in 5% to 7% of people. Constipation tends to be an ongoing issue for some patients, since all opioid-type medications slow gut motility.
Prescribing and Access
Buprenorphine products like Zubsolv are classified as Schedule III controlled substances, meaning they have accepted medical use and a lower potential for misuse than drugs in Schedules I or II. Any DEA-registered practitioner can prescribe Zubsolv, and as of February 2025, telemedicine prescribing rules allow practitioners to issue an initial six-month supply through telehealth visits. The prescriber must check your state’s prescription drug monitoring program before writing the prescription, and the pharmacist will verify your identity with a government-issued photo ID before dispensing it.
This telemedicine pathway has made treatment significantly more accessible, particularly for people in rural areas or those who face transportation barriers. If the prescription monitoring database is temporarily unavailable, a practitioner can still prescribe a seven-day supply while documenting the access issue.
What Treatment Looks Like
Zubsolv treatment typically begins during what’s called the induction phase. You’ll need to be in at least mild to moderate opioid withdrawal before taking your first dose. Starting the medication while opioids are still fully active in your system can trigger a sudden, uncomfortable withdrawal reaction called precipitated withdrawal. Your prescriber will guide you on how long to wait after your last opioid use before starting.
After induction, you move into the maintenance phase, where the dose is stabilized at a level that controls cravings and withdrawal without causing sedation. Many people stay on maintenance therapy for months or years. The FDA approval explicitly notes that Zubsolv should be used alongside counseling and psychosocial support, not as a standalone treatment. The medication handles the physical side of dependence, but therapy addresses the behavioral and psychological patterns that drive opioid use.